Legal & General Group
ZYNE

Legal & General Group’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

Legal & General Group’s Portfolio ZYNE Stock Details ZYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-3,994
Closed -$15K – 3487
2020
Q1 		$15K Sell
3,994
-1,134
-22% -$5.27K ﹤0.01% 3035
2019
Q4 		$31K Buy
5,128
+973
+23% +$6.65K ﹤0.01% 3034
2019
Q3 		$31K Buy
4,155
+695
+20% +$7.83K ﹤0.01% 2957
2019
Q2 		$47K Buy
+3,460
New +$39.9K ﹤0.01% 2805
2018
Q2 		– Sell
-2,436
Closed -$21K – 3401
2018
Q1 		$21K Hold
2,436
– – ﹤0.01% 3102
2017
Q4 		$30K Buy
2,436
+756
+45% +$8.66K ﹤0.01% 3064
2017
Q3 		$14K Hold
1,680
– – ﹤0.01% 3243
2017
Q2 		$30K Buy
+1,680
New +$33.4K ﹤0.01% 3044

Other funds holding ZYNE

EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
ZCA
Zeke Capital Advisors Berwyn, Pennsylvania $1.53B AUM 17.37% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Legal & General Group's ZYNE Position: Q2 2020 in Review

Legal & General Group sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q2 2020, closing a stake of 3,994 shares — an estimated $15K sold.

Legal & General Group first reported a position in ZYNE in Q2 2017 and held it in 8 quarters. The position peaked at $47K in Q2 2019. 74 funds tracked by Wall St. Rank hold ZYNE as of Q2 2020.

  • Legal & General Group reported no remaining Zynerba Pharmaceuticals, Inc position as of Q2 2020 after selling out during the quarter.
  • Legal & General Group sold 3,994 Zynerba Pharmaceuticals, Inc shares in Q2 2020, an estimated $15K.
  • Legal & General Group first reported a position in Zynerba Pharmaceuticals, Inc in Q2 2017 and held it in 8 quarters.
  • Legal & General Group's Zynerba Pharmaceuticals, Inc position peaked at $47K in Q2 2019.
  • 74 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q2 2020.

Based on Legal & General Group's 13F filing for Q2 2020, filed 14 Aug 2020.